Rising the ranks of investment may be easy but maintaining the glamor up there is quite the task. Countless are the numbers of investors who have risen the scales but do not last long enough to be recognized. Foresite Capital has noticed the remarkable contributions done by Molly He, Ph.D., a scientific researcher in next generation sequencing, and has added her as a partner. She brings along her unique expertise and impressive leadership record that are invaluable to the firm especially now it has a view of expanding.
Jim Tananbaum is the founder, the current chief executive officer, and managing director of Foresite Capital, a healthcare company that offers equity growth to future healthcare leaders with high-demand products and services in all healthcare sectors both in the private and public markets. The firm has its base in San Francisco but also expanding its operations in New York City. He has vast experience of over 25 years in healthcare, entrepreneurship, and investment. He is also the co-founder of GelTex Pharmaceuticals, Theravance, and Prospect Venture Partners. Jim is a graduate of Yale University with BS/BSEE degree and has an M.D. and M.B.A from Harvard University as well as an M.S. from Massachusetts Institute of Technology and read full article.
Under his leadership, Foresite has created an unrivaled reputation by investing in some of the big, exciting, and innovative companies in the healthcare sector. It seeks to make significant breakthroughs in clinical research and drug discovery through Dr. He’s expertise and Jim’s lacrosse camp.
Jim Tananbaum had appeared on the Forbes’ Midas List of top investors and now features for the third consecutive time. He is ranked 52 out of the top 100 venture capitalists on this year’s list. He is a leading investor in tech companies of the future aimed at creating high-value commodities for investors.Jim believes that with commitment and dedication, everything is possible.
More visit: https://www.forbes.com/profile/jim-tananbaum/